ImmuneOnco will share data in two posters at 2022 Annual Meeting of American Association for Cancer Research（AACR）

On March 28, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that data from 2 different new projects in two posters will be presented at the 2022 annual meeting of American Association for Cance......

2022-03-28

ImmuneOnco: IMM2520 invention patent was authorized by Japan Patent Office

On March 22, 2022, the bispecific antibody drug candidate (project number: IMM2520) independently developed by ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. that targets both CD47 and PD-L1 was authorized by the Japanese Patent Office (Japanese Paten......

2022-03-23

Dr. Lu, Qiying joined ImmuneOnco as Chief Medical Officer (CMO) and Senior Vice President (SVP)

On March 21, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") declared the appointment of Dr. Lu Qiying was appointed as the chief medical officer and senior vice president of our Company in March 2022, and ......

2022-03-20

Dr. Xiong, Zikai joined ImmuneOnco as Senior Vice President（SVP）

On March 15, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced the appointment of Dr. Xiong Zikai as the senior vice president (SVP) to be fully responsible for the company's BD affairs. ......

2022-03-15

ImmueOco: The Invention patent for IMM0306 was authorized by Japan Patent Office

On March 9, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") declared that IMM0306, a bispecific fusion protein targeting CD47 and CD20 was authorized by the Japan Patent Office (Japanese Patent Applicatio......

2022-03-10